Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy now. On March 16, Eli Lilly and Company (NYSE:LLY) announced that its weight-loss drug Zepbound will be available for self-pay starting at $299 per month for the 2.5 mg dose through LillyDirect and major pharmacies, expanding access for patients without insurance.
Pixabay/Public Domain
A new savings card allows eligible adults with a valid prescription to receive the same pricing nationwide, though it applies only to the KwikPen and not other formats. Zepbound is a once-weekly injectable for adults with obesity or overweight-related conditions, including obstructive sleep apnea, and is intended to be used alongside diet and exercise, with maintenance doses typically ranging from 5 mg to 15 mg.
On March 9, Eli Lilly and Company received a significant boost in its bid to expand access to medicines to patients at lower costs. The Medicare and Medicaid services issued new implementation details that will enhance access to medications at the lowest costs.
With the new Medicare and Medicaid Services implementation details, Eli Lily is to make Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, available through the Medicare Part D participating plans. Consequently, beneficiaries will have out-of-pocket costs capped at $50 a month. Before patients reach their deductible, they will have their cost-sharing limited to $245 a month.
Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader focused on discovering, developing, and marketing medicines to treat diabetes, obesity, cancer, and immunological disorders. Known for creating products like Mounjaro, Zepbound, and insulin therapies, they aim to improve patient health outcomes worldwide.
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
